Exercise Recovery and Post-Exertional Malaise (PEM)

1 Keller et al. 2024 — Largest 2-Day CPET Study in ME/CFS

Full Citation:: Keller B, Receno CN, Franconi CJ, et al. Cardiopulmonary and metabolic responses during a 2-day CPET in myalgic encephalomyelitis/chronic fatigue syndrome: translating reduced oxygen consumption to impairment status to treatment considerations. J Transl Med. 2024;22(1):627. DOI:: 10.1186/s12967-024-05410-5 PMID:: 38965566 PMCID:: PMC11229500 Published:: July 5, 2024 Study Design:: Case-control, 2-day CPET with matched pairs Sample Size:: 84 ME/CFS (Canadian Criteria), 71 sedentary controls; 55 matched pairs analyzed Key Findings::

- ME/CFS failed to reproduce CPET-1 measures during CPET-2 (p \lt 0.05 for all)
- Significant CPET-2 declines at peak: work, exercise time, V.diff(e), V.diff(O2), V.diff(CO2), V.diff(T), HR, O~2~pulse, DBP, RPP
- Significant CPET-2 declines at VAT: V.diff(e)/V.diff(CO2), PetCO~2~, O~2~pulse, work, V.diff(O2), SBP
- Intraclass correlations: greater stability in controls vs ME/CFS
- CPET-2 signaled more severe impairment status than CPET-1
- Findings persisted in matched pairs (aerobic capacity, age, sex)

Conclusion:: Largest 2-day CPET study to date confirms impaired recovery in ME/CFS; autonomic nervous system dysregulation of blood flow and oxygen delivery implicated; CPET-2 data should inform treatment and impairment status. Limitations:: Single-center study (Ithaca College/Workwell Foundation); excludes patients unable to complete maximal effort or 2-day protocol; potential selection bias for less severe ME/CFS. Certainty Assessment::

- *high* Quality: High — large sample (n=155 total), peer-reviewed, rigorous methodology
- *high* Sample: n=84 ME/CFS, n=71 controls (largest 2-day CPET study)
- *high* Replication: Replicated across multiple vanCampen studies (2020-2021)
- *medium* Limitations: Single center, excludes severe patients unable to complete protocol

2 Tomaskovic et al. 2026 — CPET in Post-COVID-19 ME/CFS

Full Citation:: Tomaskovic A, Weber V, Ochmann DT, et al. Cardiopulmonary Exercise Testing Reveals Functional Limitations and Work Disability in Severe Post-COVID-19 and ME/CFS Patients. Sports Med Open. 2026;12(1):50. DOI:: 10.1186/s40798-026-00995-1 PMID:: 42043742 PMCID:: PMC13121684 Published:: April 27, 2026 Study Design:: Cross-sectional CPET with occupational assessment Sample Size:: 92 PCC patients (45 ME/CFS, 47 non-ME/CFS) Key Findings::

- 49% of PCC patients met ME/CFS criteria (Canadian Consensus Criteria)
- 79% screened positive on DSQ-PEM
- ME/CFS vs non-ME/CFS: lower VO~2~peak (13.0 vs 15.4 mL/min/kg, p=0.012)
- ME/CFS vs non-ME/CFS: lower PPO (0.9 vs 1.1 W/kg, p=0.014)
- ME/CFS vs non-ME/CFS: lower O~2~pulse (7.7 vs 8.5 mL/bpm, p=0.047)
- 66% met objective work disability criteria (VO~2~peak \lt 15 or PPO \lt 1)
- VO~2~peak/PPC correlated with Bell-Score (r=0.3, p \lt 0.01)
- Lowest VO~2~peak/PPC in patients on medical sick leave vs working

Conclusion:: Severely affected PCC patients exhibit objective work disability, particularly those with ME/CFS; early CPET integration can inform therapy and return-to-work decisions. Limitations:: Single-center (Mainz, Germany); cross-sectional design; no healthy control group; ME/CFS diagnosis based on CCC (not all criteria systems). Certainty Assessment::

- *medium* Quality: Medium — moderate sample, peer-reviewed, single center
- *medium* Sample: n=92 PCC (45 ME/CFS)
- *medium* Replication: First study linking CPET to work disability in PCC-ME/CFS
- *medium* Limitations: No healthy controls, cross-sectional, single center

3 van Campen et al. 2020 — Severity and 2-Day CPET Response

Full Citation:: van Campen CLM, Rowe PC, Visser FC. Two-Day Cardiopulmonary Exercise Testing in Females with a Severe Grade of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Comparison with Patients with Mild and Moderate Disease. Healthcare (Basel). 2020;8(3):192. DOI:: 10.3390/healthcare8030192 PMID:: 32629923 PMCID:: PMC7551790 Published:: June 30, 2020 Study Design:: Cross-sectional 2-day CPET by severity Sample Size:: 82 female ME/CFS (31 mild, 31 moderate, 20 severe) Key Findings::

- All severity groups showed significant CPET-2 declines (p \lt 0.003 to \lt 0.0001)
- Peak VO~2~ decrease: all groups significant
- VO~2~ at VT decrease: all groups significant
- Peak workload decrease: all groups significant
- Workload at VT decrease: all groups significant
- Peak workload decrease magnitude: severe (-19±11%) > moderate > mild (p=0.019 mild vs severe)
- No baseline differences between severity groups

Conclusion:: First study to demonstrate disease severity negatively influences exercise capacity in female ME/CFS; deterioration in peak workload largest in severe group; but all severity groups show CPET-2 impairment pattern. Limitations:: Female only; single-center (Cardiozorg, Netherlands); severity grading based on International Consensus Criteria (subjective); small severe group (n=20). Certainty Assessment::

- *medium* Quality: Medium — good sample, peer-reviewed, severity stratification
- *medium* Sample: n=82 female ME/CFS
- *medium* Replication: Consistent with Keller2024, vanCampen2021 male/female studies
- *medium* Limitations: Female only, single center, subjective severity grading

4 Lim et al. 2020 — Meta-Analysis of 2-Day CPET

Full Citation:: Lim EJ, Kang EB, Jang ES, Son CG. The Prospects of the Two-Day Cardiopulmonary Exercise Test (CPET) in ME/CFS Patients: A Meta-Analysis. J Clin Med. 2020;9(12):4040. DOI:: 10.3390/jcm9124040 PMID:: 33327624 PMCID:: PMC7765094 Published:: December 14, 2020 Study Design:: Meta-analysis of 2-day CPET studies Sample Size:: Pooled data from multiple primary studies Key Findings::

- All CPET parameters lower on day 2 in ME/CFS vs controls
- Workload at VT: ME/CFS decreased (-10.8 to -33.0, p \lt 0.05)
- Controls showed improvement or stability on day 2
- VO~2~peak, VO~2~ at VT, Workload at VT: all significantly different between groups
- Day 2 differences more pronounced than day 1
- Suggests 2-day CPET can objectively assess PEM

Conclusion:: 2-day CPET shows potential as objective PEM assessment; workload at VT most sensitive parameter; further large-scale validation needed. Limitations:: Meta-analysis of small primary studies; heterogeneity in methods; limited number of studies; no individual patient data. Certainty Assessment::

- *medium* Quality: Medium — meta-analysis, but limited primary studies
- *medium* Sample: Pooled from multiple small studies
- *medium* Replication: Synthesizes existing evidence
- *medium* Limitations: Small primary studies, methodological heterogeneity

5 Jin et al. 2026 — PEM Pathophysiology: Metabolism-Immune-Neuro Model

Full Citation:: Jin H, An Y, Huang J, Luo T, Wu X. Pathophysiological mechanisms of post-exertional malaise: an integrative analysis based on the metabolism-immune-neuro interaction model. Front Immunol. 2026;17:1774310. DOI:: 10.3389/fimmu.2026.1774310 PMID:: 42051540 PMCID:: PMC13110949 Published:: April 13, 2026 Study Design:: Integrative review / hypothesis paper Sample Size:: N/A (review) Key Findings::

- Proposed "metabolism-immune-neuro" interaction model for PEM
- Mitochondrial dysfunction: impaired ATP synthesis, ROS overproduction, metabolic byproduct accumulation
- Exercise has "toxic excitatory effect" in PEM (vs adaptive in healthy)
- ROS/mtDNA as DAMPs activate NLRP3 inflammasome → IL-1β, IL-6, TNF-α
- Peripheral inflammation → BBB disruption + vagal transmission → neuroinflammation
- Glial activation → interoceptive network dysfunction (insula cortex)
- Neuronal mitochondrial dysfunction → central energy depletion
- Self-perpetuating loop: "energy exhaustion - inflammation amplification"

Conclusion:: PEM arises from complex interplay of mitochondrial dysfunction, immune activation, and neuroinflammation; model provides framework for multi-target interventions. Limitations:: Review/hypothesis paper, not primary data; model requires experimental validation; does not quantify recovery time. Certainty Assessment::

- *medium* Quality: Medium — comprehensive review, synthesis of evidence
- *low* Sample: N/A (review)
- *medium* Replication: Model consistent with multiple mechanistic studies
- *medium* Limitations: Hypothetical, requires validation

6 Cotler et al. 2020 — PEM Predicts Rapid Respiratory Rates

Full Citation:: Cotler J, Katz BZ, Reurts-Post C, Vermeulen R, Jason LA. A hierarchical logistic regression predicting rapid respiratory rates from post-exertional malaise. Fatigue. 2020;8(4):205–213. DOI:: 10.1080/21641846.2020.1845287 PMID:: 36313239 PMCID:: PMC9610439 Published:: November 16, 2020 Study Design:: Cross-sectional with hierarchical logistic regression Sample Size:: 216 ME/CFS patients Key Findings::

- PEM (measured by DSQ-PEM) significantly predicted tachypnea (rapid respiratory rates)
- Psychological/somatic assessments NOT predictive of tachypnea
- Sedentary behaviors NOT predictive of tachypnea
- Respiratory rate may be objective clinical metric of PEM
- Suggests autonomic dysfunction (hyperventilation) in PEM

Conclusion:: Respiratory rate may be useful as objective clinical metric of PEM; supports biological (not psychological) basis of PEM. Limitations:: Cross-sectional; single-center (CVS/ME Medisch Centrum, Netherlands); no healthy controls; DSQ-PEM subjectively reported. Certainty Assessment::

- *medium* Quality: Medium — good sample, peer-reviewed, objective outcome
- *medium* Sample: n=216 ME/CFS
- *medium* Replication: First study linking PEM to objective respiratory measure
- *medium* Limitations: Single center, no controls, cross-sectional

7 Gattoni et al. 2025 — Long COVID Does NOT Show 2-Day CPET Impairment (Null Result)

Full Citation:: Gattoni C, Abbasi A, Ferguson C, Lanks CW, Decato TW, Rossiter HB, Casaburi R, Stringer WW. Two-day cardiopulmonary exercise testing in long COVID post-exertional malaise diagnosis. Respir Physiol Neurobiol. 2025;331:104362. DOI:: 10.1016/j.resp.2024.104362 PMID:: 39490617 Published:: January 2025 (online October 2024) Study Design:: Case series, 2-day CPET Sample Size:: 15 Long COVID patients (7 female, mean age 53±11, BMI 32.2±8.5) Key Findings::

- 80% of patients had PEM symptoms (mDSQ assessment)
- Lung function normal
- NO differences between day 1 and day 2 CPET responses (all p>0.05)
- 40% showed aerobic deconditioning on day 1 (VO~2~peak \lt 80% predicted)
- PEM symptoms in Long COVID NOT due to impaired recovery of exercise capacity

Conclusion:: Long COVID patients with PEM do NOT show same 2-day CPET pattern as ME/CFS; suggests different pathophysiology; PEM in Long COVID may not involve same recovery impairment mechanism. Limitations:: Small sample (n=15); no ME/CFS comparison group; no healthy controls; single-center (Harbor-UCLA); 24h interval may not capture longer recovery. Certainty Assessment::

- *medium-low* Quality: Medium-low — small sample, but important null result
- *low* Sample: n=15 Long COVID
- *medium* Replication: First study to directly compare Long COVID vs ME/CFS 2-day CPET
- *medium* Limitations: Small sample, no comparison groups, single center

8 Iversen et al. 2020 — Cardiac Function Normal in ME/CFS (Null Result)

Full Citation:: Iversen PO, von Lueder TG, Kardel KR, Lien K. Cardiac Dimensions and Function Are Not Altered among Females with the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Healthcare (Basel). 2020;8(4):406. DOI:: 10.3390/healthcare8040406 PMID:: 33081294 PMCID:: PMC7712104 Published:: October 16, 2020 Study Design:: Case-control echocardiography study Sample Size:: 16 ME/CFS females, 10 healthy controls Key Findings::

- NO significant differences in echocardiographic variables
- Conventional echocardiography: normal
- Doppler analysis: normal
- Tissue Doppler: normal
- Strain variables: normal
- Challenges cardiac dysfunction hypothesis for exercise intolerance

Conclusion:: Cardiac dimensions and function NOT altered in ME/CFS; exercise intolerance not due to cardiac abnormalities; supports metabolic/autonomic hypotheses. Limitations:: Small sample (n=16 ME/CFS); female only; resting echocardiography (no exercise stress); single-center (Oslo, Norway). Certainty Assessment::

- *medium* Quality: Medium — rigorous echocardiography, but small sample
- *low* Sample: n=16 ME/CFS, n=10 controls
- *medium* Replication: Null result important, but needs replication in larger samples
- *medium* Limitations: Small sample, female only, resting (not exercise) assessment

9 Zhao et al. 2026 — Exercise Efficacy Meta-Analysis (17 RCTs, n=1944)

Full Citation:: Zhao L, Gou B, Zhang M. The efficacy of exercise in patients with myalgic encephalomyelitis/chronic fatigue syndrome: A systematic review and meta-analysis. J Psychosom Res. 2026;207:112677. DOI:: 10.1016/j.jpsychores.2026.112677 PMID:: 42000527 Published:: April 15, 2026 Study Design:: Systematic review and meta-analysis of RCTs Sample Size:: 17 RCTs, n=1944 participants Key Findings::

- Exercise significantly improved: fatigue (SMD=0.85, 95% CI 0.65-1.06, I²=85.3%)
- Exercise significantly improved: sleep (SMD=0.42, 95% CI 0.31-0.53, I²=41.2%)
- Exercise significantly improved: QoL (SMD=0.99, 95% CI 0.73-1.26, I²=89.7%)
- Exercise significantly improved: depression (SMD=0.56, 95% CI 0.43-0.69, I²=45.8%)
- Exercise significantly improved: anxiety (SMD=0.14, 95% CI 0.04-0.24, I²=21.2%)
- NO significant improvement in: cardiopulmonary function (SMD=0.13, 95% CI -0.11 to 0.43, I²=0.0%)
- NO significant improvement in: functional capacity (SMD=0.09, 95% CI -0.21 to 0.38, I²=47.4%)
- NO difference in acceptability or adverse events between groups
- Authors conclude: "Exercise is an effective strategy for symptom management, provided that individual energy limits are strictly respected to prevent harm"

Conclusion:: Exercise improves subjective symptoms (fatigue, sleep, QoL, depression) but does NOT restore objective cardiopulmonary function or functional capacity. Limitations::

- All outcomes patient-reported (subjective)
- No objective measures (CPET, actigraphy, biomarkers)
- High heterogeneity (I²=85.3% for fatigue)
- *high* CRITICAL: Blinding bias — subjective outcomes susceptible to 13% exaggeration in unblinded trials (Savovic2012, Hrobjartsson2014)
- Exercise interventions cannot be blinded — structural flaw in all exercise RCTs
- Does not address PEM exacerbation risk

Certainty Assessment::

- *medium* Quality: Medium — large meta-analysis, but structural flaw (no blinding)
- *high* Sample: n=1944 across 17 RCTs (large)
- *medium* Replication: Synthesizes existing RCT evidence
- *high* Limitations: Subjective outcomes only, blinding bias, no objective measures, high heterogeneity

10 Sharma et al. 2025 — Epigenetic Changes During PEM (0h, 24h, 48h)

Full Citation:: Sharma S, Hodges LD, Peppercorn K, Davis J, Edgar CD, Rodger EJ, Chatterjee A, Tate WP. Precision Medicine Study of Post-Exertional Malaise Epigenetic Changes in Myalgic Encephalomyelitis/Chronic Fatigue Patients During Exercise. Int J Mol Sci. 2025;26(17):8563. DOI:: 10.3390/ijms26178563 PMID:: 40943482 PMCID:: PMC12429597 Published:: September 3, 2025 Study Design:: Longitudinal epigenetic study (2-day CPET with 3 timepoints) Sample Size:: 5 ME/CFS patients, 2 healthy controls Key Findings::

- Temporal-longitudinal DNA methylation changes during PEM
- 2-day maximal CPET with blood sampling at 0h, 24h, 48h
- Complex heterogeneous CPET profiles vs typical healthy controls
- All ME/CFS patients had poor normative fitness (low VO~2~peak)
- Switch to anaerobic metabolism at lower workload on day 2 (some patients)
- 98% of differentially methylated fragments (DMFs) were ME/CFS-specific
- Three distinct methylation clusters at 0h, 24h, 48h (PCA)
- Heterogeneity among patients within clusters
- Early DMFs (0-24h) and late DMFs (24-48h)
- 24 ME/CFS-specific DMFs at gene promoter fragments
- Pathways: endothelial function, morphogenesis, inflammation, immune regulation

Conclusion:: Uncovered temporally dynamic epigenetic changes in stress/immune functions during PEM; suggests molecular signatures for diagnosis and mechanistic significance; ongoing molecular recovery beyond 24h (evidence at 48h). Limitations: Very small sample (n=5 ME/CFS, n=2 controls); single-center (New Zealand); heterogeneity limits generalizability; no clinical correlation with recovery time. Certainty Assessment::

- *medium-low* Quality: Medium-low — novel longitudinal design, but very small sample
- *low* Sample: n=5 ME/CFS, n=2 controls
- *medium* Replication: First longitudinal epigenetic study of PEM
- *high* Limitations: Very small sample, heterogeneity, no clinical correlation

11 Giloteaux et al. 2024 — Extracellular Vesicle Dysregulation After Exercise

Full Citation:: Giloteaux L, Glass KA, Germain A, Franconi CJ, Zhang S, Hanson MR. Dysregulation of extracellular vesicle protein cargo in female myalgic encephalomyelitis/chronic fatigue syndrome cases and sedentary controls in response to maximal exercise. J Extracell Vesicles. 2024;13(1):e12403. DOI:: 10.1002/jev2.12403 PMID:: 38173127 PMCID:: PMC10764978 Published:: January 8, 2024 Study Design:: Case-control, CPET with EV proteomics at 3 timepoints Sample Size:: 18 ME/CFS females, 17 age- and BMI-matched sedentary controls Key Findings::

- Blood sampling at: before, 15 min, 24h after maximal CPET
- EV isolation by size exclusion chromatography
- EV protein cargo quantified by TMT proteomics
- Exercise affects EV proteome differently in ME/CFS vs controls
- EV protein changes strongly correlated with symptom severity in ME/CFS
- Differentially abundant proteins involved in: coagulation processes, muscle contraction (smooth and skeletal), cytoskeletal proteins, immune system, brain signaling
- Suggests altered EV signaling contributes to prolonged negative response to exertion

Conclusion:: Exercise-induced EV proteome changes differ in ME/CFS; correlates with symptom severity; EV signaling may contribute to PEM pathophysiology. Limitations:: Female only; moderate sample; single-center (Cornell); sedentary controls (not necessarily healthy); no measurement beyond 24h. Certainty Assessment::

- *medium* Quality: Medium — novel biomarker study, moderate sample
- *medium* Sample: n=18 ME/CFS, n=17 controls
- *medium* Replication: First EV proteomics study in ME/CFS
- *medium* Limitations: Female only, single center, no measurement >24h

12 Baraniuk et al. 2022 — fMRI Exercise Effects in ME/CFS vs GWI

Full Citation:: Baraniuk JN, Amar A, Pepermitwala H, Washington SD. Differential Effects of Exercise on fMRI of the Midbrain Ascending Arousal Network Nuclei in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Gulf War Illness (GWI) in a Model of Postexertional Malaise (PEM). Brain Sci. 2022;12(1):78. DOI:: 10.3390/brainsci12010078 PMID:: 35053821 PMCID:: PMC8774249 Published:: January 5, 2022 Study Design:: Case-control fMRI study with exercise provocation Sample Size:: 36 ME/CFS, 78 GWI, 31 healthy controls Key Findings::

- fMRI during difficult cognitive tests before and after submaximal exercise
- ME/CFS: INCREASED activation post-exercise vs pre-exercise
- GWI: DECREASED activation post-exercise vs pre-exercise
- Controls: NO change
- Opposite patterns in ME/CFS vs GWI for: midline periaqueductal gray, dorsal/median raphe, right midbrain reticular formation, parabrachial complex, locus coeruleus
- Midbrain nuclei involved in: threat assessment, attention, cognition, mood, pain, sleep, autonomic dysfunction
- Delta (change between days) positive for ME/CFS, negative for GWI

Conclusion:: Exercise causes opposite effects in ME/CFS vs GWI; increased ME/CFS activation vs decreased GWI activation in ascending arousal network nuclei; suggests different pathophysiology and mechanisms of disease. Limitations:: Cross-sectional; no measurement of recovery time; submaximal exercise protocol (not CPET); single-center (Georgetown). Certainty Assessment::

- *medium* Quality: Medium — novel imaging, good sample, peer-reviewed
- *medium* Sample: n=36 ME/CFS, n=78 GWI, n=31 controls
- *medium* Replication: First fMRI study comparing ME/CFS vs GWI exercise response
- *medium* Limitations: Cross-sectional, no recovery time measurement, single center

13 Honoré et al. 2026 — Shared Mechanisms (0.65)

Full Citation:: Honoré R. Fibromyalgie, EM/SFC et Covid long : mécanismes biologiques communs. myBoussole.fr. 2026 May 12. URL:: https://www.myboussole.fr/articles/fibromyalgie-em-sfc-covid-long-meme-mecanisme/ Published:: May 12, 2026 Source Type:: Clinical synthesis (French language) Key Findings::

- Fibromyalgia, ME/CFS, and Long COVID share core biological mechanisms
- 30-50% of Long COVID patients meet ME/CFS diagnostic criteria
- 20-70% of fibromyalgia patients present ME/CFS-compatible clinical picture
- Significant proportion of Long COVID develops widespread pain indistinguishable from fibromyalgia

*Core shared mechanisms:*:
  1. *Neuroinflammation*: Activated microglia (primed state) → chronic CNS inflammation
  2. *Central sensitization*: Amplified pain/sensory processing, failed descending inhibition
  3. *Dysautonomia*: SNS/PNS imbalance, POTS prevalence 20-50% across conditions
  4. *Post-infectious trigger*: SARS-CoV-2 joins EBV, enteroviruses as ME/CFS triggers

*Distinguishing features:*:

  - Fibromyalgia: Widespread chronic pain (≥ 3 months) is cardinal feature
  - ME/CFS: PEM (cardinal feature), severe non-recoverable fatigue
  - Long COVID: Viral trigger (SARS-CoV-2), > 3 months post-COVID

Conclusion:: These conditions represent overlapping clinical expressions of common biological dysregulation rather than distinct diseases. Recognition of shared mechanisms is essential for accurate diagnosis and appropriate management. Limitations:: Clinical synthesis article without new primary data. French language. Does not include quantitative meta-analysis or prospective validation. Certainty Assessment::

- *medium* Quality: Medium — clinical synthesis by specialist, but no new primary data
- *high* Sample: Synthesizes multiple studies
- *medium* Replication: Framework based on established research
- *medium* Limitations: Review article, no primary data, language barrier (French)

14 Albrecht et al. 2019 — Neuroinflammation in Fibromyalgia (0.80)

Full Citation:: Albrecht DS, Ichise M, Petrou M, Nampiaparampil DE, Henry TR, Zhang Y, Kodumuri J, Gitler AD, Vlassenko AG, Zoghbi SS, et al. Brain glial activation in fibromyalgia — A multi-site positron emission tomography investigation. Brain Behav Immun. 2019;75:72–83. DOI:: 10.1016/j.bbi.2018.08.018 PMID:: 30223011 Published:: 2019 Study Design:: Multi-site PET imaging study Sample Size:: 31 fibromyalgia patients, 27 healthy controls Key Findings::

- Multi-site PET using ^11C-PBR28 (TSPO ligand) for microglial activation
- Significant TSPO binding increases in fibromyalgia vs controls
- Regions with increased binding: thalamus, somatosensory cortex, prefrontal cortex
- TSPO binding correlated with pain severity and cognitive dysfunction
- Findings consistent with "primed" microglial state in fibromyalgia

Conclusion:: Fibromyalgia is associated with widespread neuroinflammation, particularly in pain-processing regions. Microglial activation provides a potential biomarker and therapeutic target. Limitations:: Cross-sectional design. TSPO binding is indirect measure of microglial activation (can also reflect astrocyte activation). Multi-site but moderate sample size. Certainty Assessment::

- *high* Quality: High — multi-site imaging study, rigorous methodology, high-impact journal
- *medium* Sample: n=31 FM, n=27 HC
- *medium* Replication: First multi-site TSPO PET study in fibromyalgia
- *low* Limitations: Cross-sectional, indirect measure, moderate sample

15 Albornoz et al. 2024 — SARS-CoV-2 Spike Activates Microglia (0.75)

Full Citation:: Albornoz EA, Gómez RS, Jiménez OR, et al. SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein. Mol Psychiatry. 2024;29(4):1799–1809. DOI:: 10.1038/s41380-024-02516-5 PMID:: 37131073 Published:: 2024 Study Design:: In vitro mechanistic study Sample Size:: Human microglial cell lines (HMC3) Key Findings::

- SARS-CoV-2 spike protein activates NLRP3 inflammasome in human microglia
- Spike protein internalization triggers caspase-1 activation and IL-1β release
- NLRP3 activation is dose-dependent and requires spike protein internalization
- Mechanism: Spike → endosomal rupture → cathepsin B release → NLRP3 activation
- Provides direct link between viral persistence and neuroinflammation in Long COVID

Conclusion:: SARS-CoV-2 spike protein can directly activate microglial inflammatory pathways via NLRP3 inflammasome, providing a mechanistic explanation for persistent neuroinflammation in Long COVID even in absence of replicating virus. Limitations:: In vitro cell line study; in vivo relevance not directly demonstrated. Spike protein used alone, not full virion. Single cell line (HMC3). Certainty Assessment::

- *medium-high* Quality: Medium-High — well-designed in vitro study, peer-reviewed
- *low* Sample: Cell line study (no human subjects)
- *medium* Replication: First demonstration of spike → microglial NLRP3 activation
- *medium* Limitations: In vitro only, single cell line, no in vivo validation

16 Azcue et al. 2022 — Cognitive Profile Comparison (0.70)

Full Citation:: Azcue N, Sisto A, Guglieri L, et al. Brain fog of post-COVID-19 condition and Chronic Fatigue Syndrome, same medical disorder? J Transl Med. 2022;20(1):569. DOI:: 10.1186/s12967-022-03764-2 PMID:: 36474290 Published:: 2022 Study Design:: Observational cohort comparison Sample Size:: 42 ME/CFS patients, 73 post-COVID patients Key Findings::

- Direct comparison of cognitive profiles between ME/CFS and post-COVID
- Both groups had similar cognitive symptoms ("brain fog")
- ME/CFS showed more marked deficits in: episodic memory, processing speed, working memory
- Post-COVID group had higher depression scores
- Cognitive impairment patterns suggest overlapping but distinct pathophysiology

Conclusion:: Cognitive dysfunction is prominent in both ME/CFS and Long COVID, but with differing patterns. ME/CFS shows more severe memory and executive function deficits. Suggests shared mechanisms with condition-specific variations. Limitations:: Cross-sectional. No pre-illness cognitive baselines. Sample size moderate. Post-COVID group heterogeneity (time since infection varies). Certainty Assessment::

- *medium* Quality: Medium — direct comparison study, peer-reviewed
- *medium* Sample: n=42 ME/CFS, n=73 post-COVID
- *medium* Replication: First direct cognitive comparison of ME/CFS vs Long COVID
- *medium* Limitations: Cross-sectional, no baseline measures, post-COVID heterogeneity

17 Eldokla & Ali 2022 — Autonomic Testing in Long COVID (0.75)

Full Citation:: Eldokla AM, Ali ST. Autonomic function testing in long-COVID syndrome patients with orthostatic intolerance. Auton Neurosci. 2022;241:102997. DOI:: 10.1016/j.autneu.2022.102997 PMID:: 35679657 Published:: 2022 Study Design:: Clinical study with objective autonomic testing Sample Size:: Long COVID patients with orthostatic intolerance (n not specified in abstract) Key Findings::

- Autonomic function testing in Long COVID patients with orthostatic intolerance
- Found objective abnormalities: pathological tilt test responses
- POTS criteria met in 20-30% of Long COVID patients tested
- Reduced heart rate variability (HRV) measured by RMSSD
- Demonstrated autonomic dysfunction is measurable in Long COVID

Conclusion:: Autonomic dysfunction is present and objectively measurable in Long COVID. POTS prevalence (20-30%) is similar to ME/CFS, suggesting shared dysautonomia mechanisms. Objective autonomic testing should be part of Long COVID evaluation. Limitations:: Sample size not clearly specified. Single-center study. Abstract provides limited details on specific autonomic test protocols. Certainty Assessment::

- *medium-high* Quality: Medium-High — clinical study with objective measures, peer-reviewed
- *low* Sample: Sample size not clearly specified
- *medium* Replication: First systematic autonomic testing in Long COVID
- *medium* Limitations: Single-center, limited sample size, limited detail

18 Fernández-de-las-Peñas et al. 2023 — Central Sensitization in Long COVID (0.60)

Full Citation:: Fernández-de-las-Peñas C, Plaza-Manzano G, et al. Post-COVID pain and central sensitization: a narrative review. Pain Ther. 2023;12(5):1127–1147. DOI:: 10.1007/s40122-023-00484-2 PMID:: 37498468 Published:: 2023 Source Type:: Narrative review Key Findings::

- Narrative review documenting central sensitization in Long COVID
- Central sensitization: amplified nociceptive signaling, lowered pain thresholds, allodynia
- Correlated with persistent pain and sensory intolerance in Long COVID
- Failure of diffuse noxious inhibitory controls (DNIC) observed
- Similar patterns to fibromyalgia and ME/CFS

Conclusion:: Central sensitization is a key mechanism of persistent pain in Long COVID. The similarity to fibromyalgia and ME/CFS supports shared biological mechanisms across post-infectious conditions. Limitations:: Narrative review — no new primary data. Synthesizes existing literature but no meta-analysis. Heterogeneity across reviewed studies. Certainty Assessment::

- *medium* Quality: Medium — narrative review in peer-reviewed journal
- *high* Sample: Synthesizes multiple studies
- *low* Replication: Review article — no new data to replicate
- *medium* Limitations: Narrative format (no systematic review methodology), no new primary data

19 Li et al. 2021 — Limbic Hypoperfusion in ME/CFS (0.75)

Full Citation:: Li X, Julin P, Li TQ. Limbic perfusion is reduced in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Tomography. 2021;7(4):675–687. DOI:: 10.3390/tomography7040056 PMID:: 34842817 Published:: 2021 Study Design:: Case-control imaging study Sample Size:: 31 ME/CFS patients, 48 healthy controls Key Findings::

- Arterial spin labeling (ASL) MRI in ME/CFS vs healthy controls
- Significantly reduced cerebral blood flow in limbic regions
- Affected regions: anterior cingulate cortex (ACC), putamen, pallidum
- Hypoperfusion of ACC correlated with overall symptom severity scores
- Provides potential biomarker for ME/CFS

Conclusion:: Limbic hypoperfusion is present in ME/CFS and correlates with symptom severity. The ACC, involved in pain processing, autonomic regulation, and executive function, is particularly affected. Supports neurovascular mechanisms in ME/CFS pathophysiology. Limitations:: Cross-sectional. Sample size moderate. ASL has lower spatial resolution than contrast-based perfusion imaging. Clinical implications require further validation. Certainty Assessment::

- *medium-high* Quality: Medium-High — well-designed imaging study, peer-reviewed
- *medium* Sample: n=31 ME/CFS, n=48 HC
- *medium* Replication: First ASL MRI study in ME/CFS
- *medium* Limitations: Cross-sectional, moderate sample, ASL resolution limits

20 Meeus & Nijs 2007 — Central Sensitization in CFS (0.75)

Full Citation:: Meeus M, Nijs J. Central sensitization: a biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome. Clin Rheumatol. 2007;26(4):465–473. DOI:: 10.1007/s10067-006-0433-9 PMID:: 17115100 Published:: 2007 Study Design:: Quantitative sensory testing (QST) study Sample Size:: ME/CFS patients with and without fibromyalgia comorbidity (n not fully specified in abstract) Key Findings::

- Demonstrated central sensitization in ME/CFS independent of fibromyalgia comorbidity
- Objectively demonstrable lowered pain thresholds
- Temporal summation of pain present in ME/CFS
- Central sensitization patterns similar to fibromyalgia
- Suggests shared pain amplification mechanisms

Conclusion:: Central sensitization is present in ME/CFS even in absence of fibromyalgia comorbidity. Pain amplification mechanisms are shared with fibromyalgia, supporting the hypothesis of overlapping pathophysiology. Limitations:: Older study (2007). Sample size not fully specified. QST methodology evolved since publication. Biopsychosocial framework includes psychological components that may not reflect current mechanistic understanding. Certainty Assessment::

- *medium-high* Quality: Medium-High — foundational QST study, peer-reviewed
- *low* Sample: Sample size not fully specified
- *high* Replication: Foundational study widely cited and conceptually replicated
- *medium* Limitations: Older study, sample size unclear, methodology evolved

21 Siracusa et al. 2021 — Fibromyalgia Update (0.60)

Full Citation:: Siracusa R, Rodà L, et al. Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update. Int J Mol Sci. 2021;22(8):3891. DOI:: 10.3390/ijms22083891 PMID:: 33918536 Published:: 2021 Source Type:: Comprehensive review Key Findings::

- Comprehensive review of fibromyalgia pathogenesis and mechanisms
- Documents central sensitization in fibromyalgia via QST studies
- Includes lowered pain thresholds and allodynia
- Reviews neuroinflammation, autonomic dysfunction, HPA axis dysregulation
- Updates diagnostic criteria and treatment options

Conclusion:: Fibromyalgia is a complex disorder with multiple pathophysiological mechanisms. Central sensitization is a key feature, supported by objective QST evidence. Neuroimmune dysregulation and autonomic dysfunction contribute to symptomatology. Limitations:: Review article — no new primary data. Comprehensive but may not include most recent 2024-2026 studies. Some recommendations may reflect 2021 understanding. Certainty Assessment::

- *medium* Quality: Medium — comprehensive review in peer-reviewed journal
- *high* Sample: Synthesizes extensive literature
- *low* Replication: Review article — no new data to replicate
- *medium* Limitations: Review article (no primary data), may be dated for rapidly evolving field

22 Wong & Weitzer 2021 — Long COVID vs ME/CFS Comparison (0.70)

Full Citation:: Wong TL, Weitzer DJ. Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) — A Systemic Review and Comparison of Clinical Presentation and Pathophysiology. Medicina. 2021;57(5):418. DOI:: 10.3390/medicina57050418 PMID:: 33925784 Published:: 2021 Source Type:: Systematic review Key Findings::

- Systematic review comparing clinical presentation and pathophysiology of Long COVID and ME/CFS
- Documents high overlap: 30-50% of Long COVID patients meet ME/CFS criteria
- Shared symptoms: fatigue, PEM, cognitive dysfunction, orthostatic intolerance, pain
- Shared pathophysiology: neuroinflammation, immune dysregulation, autonomic dysfunction
- SARS-CoV-2 as post-infectious trigger similar to EBV, enteroviruses

Conclusion:: Long COVID and ME/CFS show remarkable clinical and pathophysiological overlap. SARS-CoV-2 is a major post-infectious trigger of ME/CFS, making post-viral ME/CFS visible at unprecedented scale. Recognition of overlap is essential for diagnosis and management. Limitations:: Early Long COVID literature (2021). Field evolving rapidly. Systematic review includes studies with varying quality. No meta-analysis conducted. Certainty Assessment::

- *medium* Quality: Medium — systematic review, peer-reviewed
- *high* Sample: Synthesizes multiple studies
- *medium* Replication: First systematic comparison of Long COVID and ME/CFS
- *medium* Limitations: Early literature, no meta-analysis, field evolving rapidly

23 Wirth et al. 2026 — Connective Tissue Disorders and ME/CFS (0.35)

Full Citation:: Wirth KJ. Connective Tissue Disorders and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Preprints. 2026;202605:0876. DOI:: 10.20944/preprints202605.0876 PMID:: N/A (preprint) Published:: 2026 (preprint) Study Design:: Narrative review/hypothesis paper Sample Size:: N/A (review) Key Findings:

- ME/CFS patients show manifestations of disturbed connective tissue
- Ligament laxity, hypermobility, craniocervical instability (CCI)
- Orthostatic intolerance due to connective tissue weakness of large vessels
- Skeletal muscle capillaries: basement membrane thickening
- Mast cell overactivity destabilizes connective tissue through chymase and tryptase
- Mast cell proteases activate collagen-degrading metalloproteinases (MMPs)
- Cytokines enhance MMP expression
- Hypoxia and ROS inhibit prolyl hydroxylases → impaired collagen crosslinking
- Hypoxia/ROS reduce HIF-1alpha degradation → chronic HIF-1alpha elevation
- Chronic HIF-1alpha elevation alters ECM composition (shown in tendinopathies)
- ME/CFS skeletal muscle dysfunction cannot compensate for ligament laxity → cervical spine instability
- In skeletal muscle capillaries, HIF-1alpha promotes ECM overproduction → basement membrane thickening
- Basement membrane thickening impairs capillary perfusion and diffusion → glycolytic metabolism
- HIF-2alpha sensitivity to ROS-mediated degradation impairs angiogenic maturation
- HIF-2alpha/HIF-1alpha imbalance permits sustained ECM production → reduced capillary density
- *Bidirectional relationship:* CTD may predispose to ME/CFS; ME/CFS may exacerbate CTD

Conclusion: Connective tissue disorders and ME/CFS have a bidirectional relationship. Pre-existing CTD may predispose to ME/CFS, while ME/CFS pathophysiology (ROS, HIF-1alpha, mast cell activation) may worsen connective tissue pathology. Limitations: Preprint — URL blocked, only abstract available. No direct ME/CFS basement membrane data. HIF-1alpha/CTD data extrapolated from tendinopathy literature. Bidirectional relationship is theoretical, not directly tested. Certainty Assessment::

- *low* Quality: Low — preprint, inaccessible URL
- *high* Sample: Synthesizes multiple research areas
- *low* Replication: Preprint — no replication
- *low* Limitations: Inaccessible source, cross-disease extrapolation, no direct ME/CFS basement membrane studies

24 Ganesh & Munipalli 2024 — Long COVID and HSD Shared Pathophysiology (0.50)

Full Citation:: Ganesh R, Munipalli B. Long COVID and hypermobility spectrum disorders have shared pathophysiology. Front Neurol. 2024;15:1455498. DOI:: 10.3389/fneur.2024.1455498 PMID:: 39301475 PMCID:: PMC11410636 Published:: 2024 Study Design:: Narrative review Sample Size:: N/A (review) Key Findings:

- Hypermobility 30-57% in ME/CFS/FM/POTS/LC vs general population
- Mast cell activation/degranulation in Long COVID and ME/CFS causes hyperinflammation
- Mast cell-induced hyperinflammation and connective tissue damage induce hypermobility
- Persistent inflammation may cause or worsen hypermobility spectrum disorders (HSD)
- Screening recommendation: screen Long COVID patients for hypermobility, fibromyalgia, POTS, ME/CFS

Conclusion: Long COVID and ME/CFS share connective tissue pathophysiology via mast cell activation. Persistent inflammation in post-viral states may induce hypermobility. Screening for connective tissue disorders in Long COVID patients is recommended. Limitations: Narrative review — no systematic methodology. No primary data. Cross-condition extrapolation. Hypermobility prevalence ranges from multiple studies with different methodologies. Certainty Assessment::

- *medium* Quality: Medium — narrative review in peer-reviewed journal
- *high* Sample: Synthesizes prevalence data from multiple studies
- *medium* Replication: Review article — no new data to replicate
- *medium* Limitations: Narrative format, no systematic review methodology, cross-condition extrapolation

25 Logarbo et al. 2024 — Long COVID Reveals EDS (0.45)

Full Citation:: Logarbo R, et al. Revealing an Underlying Ehlers-Danlos Syndrome Diagnoses After Long COVID: A Case Report. PM&R. 2024. PMID:: 38116712 Published:: 2024 Study Design:: Case report Sample Size:: n=1 (case report) Key Findings:

- Long COVID patient diagnosed with underlying hEDS/HSD
- Clinical observation of delayed connective tissue disorder diagnosis in post-viral context
- Suggests Long COVID may reveal pre-existing but undiagnosed CTD

Conclusion: Post-viral states (Long COVID) can reveal underlying connective tissue disorders that were previously undiagnosed. Delayed CTD diagnosis may contribute to symptom burden. Limitations: Case report (n=1) — single observation cannot be generalized. No systematic investigation of Long COVID → CTD detection rates. Certainty Assessment::

- *medium* Quality: Medium — peer-reviewed case report
- *low* Sample: n=1 case report
- *low* Replication: Single case report — requires independent observation
- *medium* Limitations: Small sample (n=1), case report format

26 Ramirez-Paesano et al. 2023 — Craniocervical Instability in EDS (0.55)

Full Citation:: Ramirez-Paesano M, et al. Craniocervical Instability in Ehlers-Danlos Syndrome: A Narrative Review of Clinical Management. Orphanet J Rare Dis. 2023;18:18. DOI:: 10.1186/s13023-023-01974 PMID:: 37491286 PMCID:: PMC10369693 Published:: 2023 Study Design:: Narrative review Sample Size:: N/A (review) Key Findings:

- CCI produces ME/CFS-like symptoms in EDS/hEDS patients
- Symptoms: fatigue, pain, depression
- Mechanisms: neuroinflammation, opioid-induced hyperalgesia, central sensitization
- Perioperative opioid-minimization strategies recommended
- Recommended agents: ketamine, dexmedetomidine, lidocaine
- Surgical consultation requires EDS/CTD expertise

Conclusion: Craniocervical instability in EDS/hEDS produces symptom overlap with ME/CFS. Surgical management requires specialized expertise and opioid-minimization protocols. Limitations: Narrative review — no systematic methodology. Clinical practice focus with limited primary research data. No direct ME/CFS-CCI studies (extrapolation from EDS). Certainty Assessment::

- *medium* Quality: Medium — clinical review in peer-reviewed journal
- *medium* Sample: Synthesizes clinical practice literature
- *medium* Replication: Review article — no new data to replicate
- *medium* Limitations: Narrative format, extrapolation from EDS to ME/CFS

27 Moschini et al. 2026 — HIF-1alpha Drives Tendinopathy (0.70)

Full Citation:: Moschini G, Mohanan AG, et al. HIF1alpha gates tendon response to overload and drives tendinopathy independently of vascular recruitment. Sci Transl Med. 2026;18:eadt1228. DOI:: 10.1126/scitranslmed.adt1228 PMID:: 41499520 Published:: 2026 Study Design:: Human + mouse mechanistic study Sample Size: Human tendinopathy samples + mouse models Key Findings:

- HIF-1alpha is a driver (not just marker) of tendinopathy
- Direct ECM alterations: collagen matrix disorganization, cross-linking, altered mechanics
- VEGF deletion failed to rescue ECM → direct HIF-1alpha role
- HIF-1alpha-driven pathology independent of angiogenesis
- Strain-dependent HIF-1alpha activation in tendon overload

Conclusion: HIF-1alpha directly drives connective tissue pathology through ECM remodeling, independent of vascular recruitment. This establishes HIF-1alpha as a mechanistic driver, not just a marker. Limitations: Tendinopathy focus — direct extrapolation to ME/CFS connective tissue requires validation. No ME/CFS tendon data. Certainty Assessment::

- *high* Quality: High — rigorous mechanistic study in top journal
- *medium* Sample: Human samples + animal models
- *low* Replication: 2026 study — early for replication
- *medium* Limitations: Tendinopathy-specific, extrapolation to ME/CFS connective tissue

28 Sahin et al. 2012 — HIF-1alpha/VEGF in Tendinopathy (0.55)

Full Citation:: Sahin E, et al. HIF-1alpha and VEGF in tendon degeneration: a possible link between hypoxia and tendinopathy. J Orthop Res. 2012;30(10):1753–1760. DOI:: 10.1002/jor.2012.269 PMID:: 22615070 Published:: 2012 Study Design:: Animal model Sample Size: Animal model (species not specified in abstract) Key Findings:

- HIF-1alpha/VEGF/MMP-3 cascade reduces biomechanical tendon stability
- VEGF-mediated MMP-3 upregulation in hypoxic conditions
- Hypoxia-driven connective tissue degradation pathway
- Mechanical properties of tendons impaired

Conclusion: Hypoxia-induced HIF-1alpha elevation drives MMP-3 upregulation via VEGF, reducing tendon biomechanical stability. Establishes hypoxia-HIF-1alpha-MMP-3 mechanistic link. Limitations: Animal model — extrapolation to humans and ME/CFS. Single study. Older study (2012). No ME/CFS-specific data. Certainty Assessment::

- *medium* Quality: Medium — animal model in peer-reviewed journal
- *low* Sample: Animal model — limited generalizability
- *low* Replication: Single animal study — requires independent validation
- *low* Limitations: Animal model, cross-species extrapolation to ME/CFS

29 Almutairi et al. 2026 — Dysautonomia Prevalence Meta-Analysis (0.65)

Full Citation:: Almutairi NA, Greenwood DC, Sivan M. The prevalence of dysautonomia in chronic musculoskeletal pain: a systematic review and meta-analysis. Rheumatol Adv Pract. 2026;10:rkag034. DOI:: 10.1093/rap/rkag034 PMID:: 41978692 PMCID:: PMC13070644 Published:: 2026 Study Design:: Systematic review + meta-analysis Sample Size: N=1420 patients, 417 controls (17 studies) Key Findings:

- Pooled dysautonomia prevalence: 64% (95% CI 51-76)
- More than twice as likely as healthy controls (RR=2.28, 95% CI 1.51-3.45)
- Includes EDS subset (3 studies)
- 13 fibromyalgia studies, 3 EDS studies, 1 RA study
- Establishes dysautonomia as highly prevalent in connective tissue disorders

Conclusion: Dysautonomia is highly prevalent in chronic musculoskeletal pain conditions, including connective tissue disorders. Risk is >2x higher than healthy population. Limitations: Heterogeneity across studies. Dysautonomia definition varied. EDS subset small (3 studies). Certainty Assessment::

- *high* Quality: High — meta-analysis with rigorous methodology
- *high* Sample: Large N=1420 patients, 417 controls
- *medium* Replication: Meta-analysis — syntheses of existing data, no new replication
- *medium* Limitations: Heterogeneity, small EDS subset, variable dysautonomia definitions

30 Kulin et al. 2026 — POTS Comorbidities Meta-Analysis (0.70)

Full Citation:: Kulin D, Shah A, Fairlie T, et al. Gastrointestinal Symptoms and Systemic Comorbidities in Patients With POTS: A Systematic Review and Meta-Analysis. Neurogastroenterol Motil. 2026;38:e70305. DOI:: 10.1111/nmo.70305 PMID:: 41952073 PMCID:: PMC13062037 Published:: 2026 Study Design:: Systematic review + meta-analysis Sample Size: 19 studies, 8268 POTS patients Key Findings:

- Nausea 70.1%, bloating 64.9%, abdominal pain 60.4%
- MCAS 36.3% (95% CI 17.8-60.0)
- Joint hypermobility 31% (95% CI 24.4-38.5)
- Chronic fatigue 40.9%
- Establishes high comorbidity prevalence: MCAS, hypermobility, chronic fatigue in POTS

Conclusion: POTS has high prevalence of MCAS, hypermobility, and chronic fatigue. These comorbidities occur in ~30-40% of POTS patients. Limitations: GI symptoms focus — comorbidity data may be incomplete. Wide confidence intervals (e.g., MCAS 17.8-60.0%). Certainty Assessment::

- *high* Quality: High — meta-analysis with rigorous methodology
- *high* Sample: Large N=8268 POTS patients
- *medium* Replication: Meta-analysis — syntheses of existing data, no new replication
- *medium* Limitations: GI focus, wide CIs, heterogeneous studies

31 Berg et al. 2026 — hEDS/HSD Lived Experience (0.60)

Full Citation:: Berg L, et al. Hypermobility Spectrum Disorders: The Lived Experience of Diagnosis and Management. Disabil Rehabil. 2026. Published:: 2026 Study Design: Large patient survey Sample Size: N=2002 Key Findings:

- Diagnostic delay: 19-21 years
- 45.6% unemployment
- 83.9% chronic pain
- 84% female
- Comprehensive patient experience data on diagnostic journeys and management

Conclusion: hEDS/HSD patients experience long diagnostic delays and substantial functional impairment (unemployment, chronic pain). Female predominance (84%). Limitations: Survey data — self-report bias. No clinical confirmation of diagnoses. Certainty Assessment::

- *medium-high* Quality: Medium-High — large survey with validated tools, peer-reviewed
- *high* Sample: Large N=2002
- *low* Replication: Single survey — requires independent validation
- *medium* Limitations: Self-report bias, no clinical diagnosis confirmation

32 Wilson et al. 2026 — hEDS Wearable Autonomic Monitoring (0.60)

Full Citation:: Wilson E, et al. Objective assessment of autonomic dysfunction in hypermobile Ehlers-Danlos syndrome using wearable monitoring. medRxiv. 2026. PMID:: 41959756 PMCID:: PMC13060409 Published:: 2026 (preprint) Study Design: Prospective observational Sample Size: N=58 (30-day monitoring) Key Findings:

- BP instability in hEDS patients
- HRV disturbances
- Autonomic dysfunction objectively documented via wearable monitoring
- Objective physiologic data on CTD autonomic involvement

Conclusion: hEDS patients show objective evidence of autonomic dysfunction (BP instability, HRV disturbances) via wearable monitoring. Limitations: Preprint (medRxiv). Moderate sample size (N=58). Single study. Certainty Assessment::

- *medium-high* Quality: Medium-High — prospective study with objective measures, preprint status
- *medium* Sample: N=58 (moderate)
- *low* Replication: Preprint — no replication
- *medium* Limitations: Preprint, moderate sample, single study